Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.13566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von David G Morgan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Neuroscience, and Alzheimer's Alliance, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloidosis, Cognitive Dysfunction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Amyloid precursor protein (APP) transgenic mice are models of Alzheimer's disease (AD) amyloidosis, not all of AD. Diffuse, compacted, and vascular deposits in APP mice mimic those found in AD cases. METHODS Most interventional studies in APP mice start treatment early in the process of amyloid deposition, consistent with a prevention treatment regimen. Most clinical trials treat patients with established amyloid deposits in a therapeutic treatment regimen. RESULTS The first treatment to reduce amyloid and cognitive impairment in mice was immunotherapy. The APP mouse models not only predicted efficacy, but presaged the vascular leakage called ARIA. The recent immunotherapy clinical trials that removed amyloid and slowed cognitive decline confirms the utility of these early APP models when used in therapeutic designs. DISCUSSION New mouse models of AD pathologies will add to the research armamentarium, but the early models have accurately predicted responses to amyloid therapies in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Neuroscience, and Alzheimer's Alliance, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.
- Department of Medical and Molecular Genetics, Stark Neurosciences Research Institute, Indianapolis, Indiana, USA.
ORCID-Profile: David G Morgan
Förderung
- NIA NIH HHS
Zitieren
APA
Morgan, D. G., & Lamb, B. T. (2024). Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13566
Vancouver
Morgan DG, Lamb BT. Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13566
BibTeX
@article{Morgan2024,
author = {Morgan, David G and Lamb, Bruce T},
title = {Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.13566}
}
EUVIMED